BioPharmSignal logoBioPharmSignal

Biotech News

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

Assertio (ASRT)AssertioFinancing

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Brendan O’Grady, Chief Executive Officer, will participate in a fireside chat discussion as part of the Maxim Group 2024 Healthcare Virtual Summit. The fireside chat with Mr. O’Grady, hosted by Maxim Group research analyst Naz Rahman, will occur Tuesday, October 15, 2024 at 1:00 pm Eastern Time.

Investors can register to listen to the event via https://m-vest.com/events/healthcare-10152024 .

About Assertio

Assertio is a commercial pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com .

Investor Contact

Matt Kreps, Managing Director Darrow Associates M: 214-597-8200 [email protected]

Related news

NGENNervGen Pharma2026-05-21 20:01 EST

NervGen Announces Proposed Public Offering of Securities

TSHATaysha Gene Therapies2026-06-25 02:34 EST

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

TSHATaysha Gene Therapies2026-06-24 20:01 EST

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NGENNervGen Pharma2026-05-22 03:27 EST

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

ANVSAnnovis Bio2026-05-20 12:00 EST

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

PRAXPraxis Precision Medicines2026-06-04 20:01 EST

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

ECORelectroCore2026-06-17 12:00 EST

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

View all latest news

Assertio

Assertio is a specialty pharmaceutical company with a portfolio of neurology, pain, and related products. The story is largely about managing a concentrated commercial base while expanding selectively.

Recent company news

ASRTAssertio2025-10-28 13:15 EST

Assertio Announces Leadership Transition

ASRTAssertio2025-09-15 13:00 EST

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

ASRTAssertio2025-09-10 11:30 EST

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

ASRTAssertio2025-09-03 12:15 EST

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025

ASRTAssertio2025-08-11 20:05 EST

Assertio Reports Second Quarter 2025 Financial Results

Stock data

Close
23.50 USD
Market cap
151.54M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States